JANUVIA – 100MG

The Brand Name JANUVIA Has Generic Salt :: SITAGLIPTIN 

JANUVIA  Is From Company MSD PH. Priced :: Rs. 299

JANUVIA have SITAGLIPTIN is comes under Sub class Insulin , Anti Diabetic drugs of  Main Class Endocrine,Steroid Hormones , Metabolic System

Main Medicine Class:: Endocrine,Steroid Hormones , Metabolic System  Sub Medicine Class :: Insulin , Anti Diabetic drugs 

 Salt Name :  OR Generic Name Form Price : MRP /Probable Packing
SITAGLIPTIN    Rs. 299  –
Brand Name Company / Manufacturers Strength Unit Price / –
 JANUVIA  MSD PH.  100MG  – Rs. 299

Company  Brand Name  Salt Combination Main Medical Class Sub Medical Class
 From MSD PH. :: JANUVIA  SITAGLIPTIN  Endocrine,Steroid Hormones , Metabolic System Insulin , Anti Diabetic drugs

Indications for Drugs ::

Type 2 diabetes mellitus

Drug Dose ::

The recommended dose of Sitagliptin is 100 mg once daily. Sitagliptin can be taken with or without food. For patients with mild renal insufficiency ( creatinine clearance [CrCl]>50ml/min), no dosage adjustment is required. Renal impairment: CrCl (ml/min) 30-<50 50 mg daily. <30 25 daily; may be given without regard to the timing of haemodialysis. pediatric use: safety and effectiveness sitagliptin in patients under 18 years age have not been established. Contraindication ::

Hypersensitivity reactions such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome can occur. Type 1 diabetes. Diabetic ketoacidosis.

Drug Precautions ::

Discontinue treatment if there are signs of hypersensitivity. Caution when used with sulphonylureas and/or other antidiabetic medications; monitor blood glucose regularly. Renal impairment; dose adjustment may be needed. Children <18 yr. pregnancy, lactation. Drug Side Effects ::

Headache, diarrhoea, upper respiratory tract infection, nasopharyngitis. Angioedema, exfoliative dermatitis. Hypoglycemia occurs in patients treated with the combination of Sitagliptin and sulfonylurea, with or without Metformin. Potentially Fatal: Anaphylaxis and/or severe dermatologic reactions such as Stevens-Johnson syndrome.

Pregnancy category ::
Pregnancy category

2

Drug Mode of Action ::  

Sitagliptin inhibits dipeptidyl peptidase IV (DPP-IV), resulting in prolonged active incretin levels. Incretin hormones increases insulin synthesis and release from pancreatic ?-cells and reduces glucagon secretion from pancreatic ?-cells. Reduced glucagon secretion leads to decreased hepatic glucose production.

Drug Interactions ::

Increased risk of hypoglycaemia when used in combination w/ sulfonylureas or insulin.

 

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Related Posts:
You May Also Like::